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Goknur Haliloglu,7 Diclehan Orhan,7 William B. Dobyns,8 Gregory M. Enns,9 Melanie Manning,9
Amanda Krause,10 Mustafa A. Salih,11 Christopher A. Walsh,4 Matthew Hurles,2 Kevin P. Campbell,3
M. Chiara Manzini,4 UK10K Consortium, Derek Stemple,2 Yung-Yao Lin,2,12 and Francesco Muntoni1,*
Mutations in several known or putative glycosyltransferases cause glycosylation defects in a-dystroglycan (a-DG), an integral
component of the dystrophin glycoprotein complex. The hypoglycosylation reduces the ability of a-DG to bind laminin and other
extracellular matrix ligands and is responsible for the pathogenesis of an inherited subset of muscular dystrophies known as the dystro-
glycanopathies. By exome and Sanger sequencing we identified two individuals affected by a dystroglycanopathy with mutations in
b-1,3-N-acetylgalactosaminyltransferase 2 (B3GALNT2). B3GALNT2 transfers N-acetyl galactosamine (GalNAc) in a b-1,3 linkage to
N-acetyl glucosamine (GlcNAc). A subsequent study of a separate cohort of individuals identified recessive mutations in four additional
cases that were all affected by dystroglycanopathy with structural brain involvement. We show that functional dystroglycan glycosyl-
ation was reduced in the fibroblasts and muscle (when available) of these individuals via flow cytometry, immunoblotting, and immu-
nocytochemistry. B3GALNT2 localized to the endoplasmic reticulum, and this localization was perturbed by some of the missense
mutations identified. Moreover, knockdown of b3galnt2 in zebrafish recapitulated the human congenital muscular dystrophy pheno-
type with reduced motility, brain abnormalities, and disordered muscle fibers with evidence of damage to both the myosepta and the
sarcolemma. Functional dystroglycan glycosylation was also reduced in the b3galnt2 knockdown zebrafish embryos. Together these
results demonstrate a role for B3GALNT2 in the glycosylation of a-DG and show that B3GALNT2mutations can cause dystroglycanop-
athy with muscle and brain involvement.Introduction
Congenital muscular dystrophies (CMDs) are a heteroge-
neous group of inherited diseases characterized by the
onset of muscle weakness at birth or within 2 years of
life and variable degrees of dystrophic changes on muscle
biopsy. A common subgroup within the CMDs are the dys-
troglycanopathies, characterized by reduced functional
glycosylation of a-dystroglycan (a-DG). The dystroglycan
gene DAG1 (MIM 128239) encodes for a protein that is
posttranslationally glycosylated and cleaved into two
noncovalently associated proteins, a-DG and b-dystrogly-
can (b-DG).1–3 a-DG is a peripheral membrane protein
that binds to several extracellular matrix components,
including laminin-a2 and other laminin-G domain con-
taining ligands,2,4 and the transmembrane protein b-DG
is anchored to the cytoskeleton by the dystrophin
complex.1 This connection helps to maintain structural
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signal transduction. The correct glycosylation of a-DG is
essential for its function as an extracellular matrix
receptor.1 Dystroglycan is not restricted to skeletal muscle
and is also present with varying degrees of glycosylation in
many tissues such as the brain, peripheral nerve, and
epithelia.5,6 In these tissues, dystroglycan has a multitude
of functions includingmorphogenesis, early development,
synaptogenesis, and signaling.7
Dystroglycanopathies have been linked to mutations
in 12 genes: Protein O-mannosyltransferase 18 (POMT1
[MIM 607423]), Protein O-mannosyltransferase 29
(POMT2 [MIM 607439]), Protein O-mannose b-1, 2-N-ace-
tylglucosaminyltransferase10 (POMGNT1 [MIM 606822]),
Fukutin11 (FKTN [MIM 607440]), Fukutin-related
protein12 (FKRP [MIM 606596]), like-acetylglucosaminyl-
transferase13 (LARGE [MIM 603590]), Dolichyl-phosphate
mannosyltransferase 214 (DPM2 [MIM 603564]), Do-
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605951]), Dolichol Kinase16 (DOLK [MIM 610746]), Isopre-
noid Synthase Domain Containing17–19 (ISPD [MIM
614631]), Glycosyltransferase-like domain containing 220
(GTDC2 [MIM 147730]), and Transmembrane protein 521
(TMEM5 [MIM 605862]). In these disorders, the reduced
a-DG glycosylation1 results in lower-affinity binding to
the extracellular matrix partners. Clinical severity in indi-
viduals with dystroglycanopathy varies markedly22–24
and is broadly related to the level of a-DG hypoglycosyla-
tion caused especially by mutations in some genes such as
POMT1, POMT2, and POMGNT122 but less so with FKTN
and FKRP,22 as assessed with antibodies that specifically
recognize glycosylated epitopes on a-DG. Individuals at
the severe end of the clinical spectrum have muscular
dystrophy with brain and eye anomalies and the resulting
clinical conditions known as Walker-Warburg syndrome
(WWS [MIM 236670]), muscle-eye-brain disease (MEB
[MIM 236670]), and Fukuyama congenital muscular
dystrophy (FCMD [MIM 253800]).These conditions are
often associated with a short life expectancy. Milder condi-
tions often exclusively affect striated muscle and can have
onset in childhood or later, as for example in limb-girdle
muscular dystrophy type 2I (LGMD2I [MIM 607155])
and congenital muscular dystrophy type 1C with no
mental retardation (MDC1C [MIM 606612]). Almost 50%
of individuals with features of a dystroglycanopathy
remain genetically uncharacterized.17,25,26
In this report we describe the identification of mutations
in b1,3-N-acetylgalactosaminyl transferase (B3GALNT2
[MIM 610194]) in individuals with dystroglycanopathy.
The clinical severity ranges from severeWWS tomilder dys-
troglycanopathy variants, invariably associated with brain
involvement. Further analysis suggests that B3GALNT2
is involved in the functional glycosylation of a-DG.Subjects and Methods
Subjects
This study covers two cohorts of affected individuals. The first
cohort consisted of 47 dystroglycanopathy individuals25 recruited
at the Dubowitz Neuromuscular Centre at Great Ormond Street
Hospital (London, UK). The second cohort consisted of 55 dystro-
glycanopathy individuals that were enrolled at Boston Children’s
Hospital (Boston, MA). All consents and local review board
approvals were in accordance with the UK10K project ethical
framework. Affected individuals P1 and P2 were identified from
the UK cohort, and P3–P7 were identified from the USA cohort.
Exome and Sanger Sequencing
P1 was whole-exome sequenced as part of the UK10K project via
the HiSeq platform (Illumina, San Diego, CA, USA) as paired-end
75 base pair (bp) reads. Sequencing, alignment of reads, and
variant calling were performed as recently described.18 The mean
coverage was 743. P3 and P6 were whole-exome sequenced by
Axeq Technologies (Seoul, Korea) with a SureSelect Human All
Exon 50 Mb enrichment kit and the Illumina HiSeq platform.
The mean coverages were 48.63 and 423, respectively. P4 was
whole-exome sequenced at the Broad Institute of Harvard andThe AmeMIT with a SureSelect Human All Exon 37 Mb enrichment kit
and the HiSeq platform (Illumina). It had a mean coverage of
1103. Additional B3GALNT2 mutations were identified in P2
and P7 by standard Sanger sequencing protocols.18 Primer
sequences are available upon request.
For P1, functional annotation was added with Ensembl Variant
Effect Predictor v2.2 against Ensembl 64 Variant filtering of the
single-nucleotide variants, and indels for P1 were done at the
B3GALNT2 locus as previously described18 assuming autosomal-
recessive inheritance. The filtering for P4 was performed similarly
as for P1 except that dbSNP132 variants were not excluded, and
variants were also filtered against 821 exomes sequenced in the
C.A.W. lab and 69 genome sequences available from Complete
Genomics. We focused on variants in regions shared with the
affected sibling. For P3, P4, and P6, functional annotation was
performed with ANNOVAR.27
Skeletal Muscle Histology and
Immunohistochemistry
Immunohistochemical studies were performed as described
previously.28 Unfixed frozen serial sections (7 mm) were incubated
with primary antibodies for 1 hr, and then with the appropriate
biotinylated secondary antibodies for 30 min followed by
streptavidin conjugated to Alexa Fluor 594 (Life Technologies,
Paisley, UK) for 15 min. Primary antibodies used were mouse
monoclonal: a-DG IIH6 (clone IIH6C4 from K.P.C.,3,29), b-DG
(Leica, Milton Keynes, UK; clone 43DAG1/8D5), laminin-a2
(Merck Millipore, Nottingham, UK; catalog no. MAB1922 clone
5H2) to the 80 kDa C-terminal fragment, and goat polyclonal
core a-dystroglycan GT20ADG.30 Sections were evaluated with
a Leica DMR microscope interfaced to MetaMorph (Molecular
Devices, Sunnyvale, CA, USA).
Plasmid Construction and Mutagenesis
Human B3GALNT2 cDNA (Image clone: IRATp970G0734D) was
obtained from Source Bioscience (Nottingham, UK). The coding
sequence of B3GALNT2 was amplified with the primers listed in
Table S1 (available online). Amplified products were cloned into
the pcDNA3.1/V5-His TOPO expression vector (Life Technologies)
according to the manufacturer’s instructions. Missense mutations
(c.740G>A [p.Gly247Glu], c.875G>C [p.Arg292Pro], c.802G>A
[p.Val268Met]) were introduced via QuickChange II site-directed
mutagenesis (Agilent Technologies, Cheshire, UK). Mutagenesis
primers are listed in Table S2.
Flow Cytometry
Functional a-DG glycosylation was assessed in P1 and P2’s fibro-
blasts with the a-DG antibody IIH6 (Merck Millipore). Fibroblasts
were grown in DMEM (Life Technologies) containing 20% fetal
bovine serum (FBS, PAA, Yeovil, UK), 2% glutamine, and 1% peni-
cillin-streptavidin (Life Technologies) at 37C with 5% CO2. The
method was modified from Rojek et al.31 Cells were detached
with Accutase (Merck Millipore), centrifuged at 500 3 g for
3 min, and resuspended to a final density of 200,000 cells/ml.
They were subsequently fixed with 2% paraformaldehyde and
washed with PBS 0.1% FBS. Subsequent centrifugations were at
3,000 3 g for 3 min. Cells were then incubated with the following
antibodies: anti-a-DG IIH6 (Merck Millipore), anti-mouse bio-
tinylated IgM (Vector Labs, Peterborough, UK), and streptavidin-
PE (BD PharMingen, Oxford, UK). Cells were resuspended in
500 ml of PBS and transferred to FACS tubes (BD Biosciences,rican Journal of Human Genetics 92, 354–365, March 7, 2013 355
Oxford, UK). Data were acquired with the Cyan ADP analyzer
(Beckman Coulter, High Wycome, UK) and analyzed with the
FlowJo software (Tree Star, Ashland, OR, USA). A separate control
for each cell population was incubated only with the secondary
antibody. Fluorescence staining observed in these cell populations
was discounted as background and removed from the correspond-
ing cell population stained with all three antibodies in order to
select for IIH6-positive cells only (unpublished data). An unpaired
two-tailed t test was utilized to interpret the flow cytometry data.
Transfection of Wild-Type and Mutant B3GALNT2
on C2C12 Cells
C2C12myoblast cells (ECCAC)were cultured in20%FBS inDMEM
supplemented with 2% L-glutamine. Transfection of cell lines
was carried out with Gene Juice (Merck Millipore) in serum-free
media. After 24 hr, cells were fixed in either 2% paraformaldehyde
or methanol for immunohistochemistry. Immunolabeling was
performed with V5-FITC (Life Technologies), ERp72 (Cell Signal-
ing Technology for New England Biolabs, Ipswich, MA, USA),
goat anti-rabbit Alexa Fluor 594 or goat anti-mouse Alexa Fluor
594 (Life Technologies), and Hoechst 33258 (Life Technologies).
Fluorescence images were taken with a Leica DMR microscope
(Molecular Devices). Metamorph image capture software was
used (Molecular Devices). Any further image processing was
achieved with ImageJ software.
Immunoblot Analysis of Human Proteins
Immunoblotting of muscle protein lysate and fibroblast cell lysate
was performed as previously described.32,33 The following anti-
bodies were used: anti-a-DG IIH6 (Merck Millipore), anti-b-DG
(Leica Microsystems, Milton Keynes, UK), biotinylated secondary
antibody anti-IgM (Dako, Glostrup, Denmark) or anti-IgG
(Dako), and HRP-streptavidin (Dako).
Knockdown of Zebrafish b3galnt2 and
Characterization of the Phenotype
To determine the expression of zebrafish b3galnt2, we extracted
RNA from 20–30 embryos with an RNeasy kit (QIAGEN, Crawley,
UK), followed by reverse transcription with SuperScript III (Life
Technologies). RT-PCR for b3galnt2 was done with RedTaq DNA
polymerase kit (Sigma-Aldrich, Dorset, UK) with forward and
reverse primers 50-ACTCAGAGCTCCGCGATG-30 and 50-CAGAG
CAGAGATCCCTCAAA-30, respectively.
Translation blocking (TB) (50-CGCCGCCGCTGCACTTCTCAT
GGAC-30) and splice blocking (SB) (50-GGTCTGTCTGTCAAGGA
GAAATAAA-30) morpholinos for b3galnt2 were obtained from
Gene Tools, LLC (Philomath, OR, USA) and injected into 1- to 4-
cell-stage Tuebingen Long Fin zebrafish embryos, which were
reared as previously described.34 Sequences of p53 and dag1 mor-
pholinos have been described.35,36
Zebrafish expression plasmids (pCS2þ) containing b3galnt2
cDNA (Image clone: IRBOp991H0563D) and a C-terminal GFP
tag were generated by Gateway Cloning Technology (Life Technol-
ogies) according to the manufacturer’s instructions. mRNA for
injection was made with mMessage mMachine SP6 kit (Ambion,
for Life Technologies). Immunofluorescence staining by primary
antibodies against laminin (L-9393, Sigma-Aldrich) and b-DG
(Leica Microsystems) was performed on 48 hr postfertilization
(hpf) whole-mount embryos as previously described.35 For the
Evans blue dye (EBD) assay, 48 hpf live embryos were immobilized
in 1% low-melting-point agarose (Sigma-Aldrich) containing356 The American Journal of Human Genetics 92, 354–365, March 70.016% tricaine (Sigma-Aldrich), and a solution of 0.1% EBD
(Sigma-Aldrich) was injected into the pericardium. Two hours
later, they were examined by confocal microscopy. Microsome
preparation and immunoblot analysis of zebrafish proteins was
performed as previously described.19Results
B3GALNT2 Is Mutated in Individuals with
Dystroglycanopathy
We diagnosed dystroglycanopathy in a single affected
individual (P1). He presented at 4months of agewith devel-
opmental delay and a head circumference above 90th
percentile. All motor milestones were delayed due to axial
hypotonia and increased limb tone due to spasticity; he
never acquired independent walking. From the age of 6
years he could take steps with hands held and used a
standing device to stand. He is a sociable boy, but his com-
munication skills are mostly confined to sign language. His
vision was also severely impaired due to marked myopia
complicated by bilateral partial retinal detachment. A brain
MRI showed cerebellar cysts, a thin corpus callosum,
diffusely abnormal white matter signal on T2-weighted
images, and cortical dysplasia in the form of frontoparietal
polymicrogyria. The diagnosis was a dystroglycanopathy
with clinical features overlapping MEB and FCMD.25
Molecular genetic analysis of the genes previously associ-
ated with dystroglycanopathies was normal.
We performed whole-exome sequencing on P1 and
variant filtering left three genes with two potentially
deleterious variants each. These were alanyl-tRNAsynthe-
tase (AARS [MIM 601065]), nesprin-2 (SYNE2 [MIM
608442]), and b-1,3-N-acetylgalactosaminyltransferase 2
(B3GALNT2). AARS mutations have been described to
cause Charcot-Marie-Tooth disease, type 2N (MIM
613287), a phenotype not present in P1. SYNE2 variants
have been associated with Emery-Dreifuss muscular
dystrophy (MIM 612999), which is very distinct from
P1’s phenotype. B3GALNT2 (RefSeq accession number
NM_152490.2) encodes for a glycosyltransferase that
synthesizes the structure GlcNac-b1, 3GalNac,37 a glycan
that has previously been found on a-DG.38,39 Mutations
in this gene could reduce the amount of functional a-DG
glycosylation by preventing or impairing the formation
of this particular glycan. P1 was compound heterozygous
for the B3GALNT2 variants c.875G>C (p.Arg292Pro)
and c.740G>A (p.Gly247Glu). We Sanger sequenced
B3GALNT2 in the remaining UK cohort and found muta-
tions in another individual of Turkish descent with
a similar phenotype (Table 1). This individual (P2) had a
history of delayed gross motor skills and was unable to
walk. His communication was limited, but his vision was
intact. His brain MRI showed features similar to those of
P1 (Figure 1). For both P1 and P2, brain involvement was
not detected in prenatal scans.
Six additional mutations in B3GALNT2 were subse-
quently identified in four individuals by exome, 2013
Table 1. Mutations and Predicted Protein Changes for P1–P4, P6, and P7
Affected
Persona Mutationsb
Predicted Protein
Effect
Mutation Detection
Technique
Parental Carrier
Status
P1 (M) exon 6: c.740G>A p.Gly247Glu exome mother: carrier
exon 8: c.875G>C p.Arg292Pro father: carrier
P2 (M) exon 1: c.51_73dup (homozygous) p.Ser25Cysfs*38 Sanger sequencing father: carrier
mother: carrier
P3 (F) exon 6: c.726_727del p.Val243Glufs*2 exome mother: carrier
exon 7: c.822_823dup p.Ile276Leufs*26 no paternal DNA
P4 (M) exon 3: c.308_309del p.Val103Glyfs*10 exome mother: carrier
exon 6: c.755T>G p.Val252Gly father: carrier
P6 (F) exon 7: c.802G>A (homozygous) p.Val268Met exome father: carrier
mother: carrier
P7 (M) exon 12: c.1423C>T (homozygous) p.Gln475* Sanger sequencing no parental DNA
aAffected person’s sex in brackets: M, male; F, female. DNA was not available for P5.
bMutation nomenclature follows the recommended guidelines of the Human Genome Variation Society with the nucleotide numbering based on GenBank refer-
ence sequence NM_152490.2 and verified with Mutalyzer 2.0.beta-21. Nucleotide numbering denotes the adenosine of the annotated translation start codon as
nucleotide position þ1.sequencing (P3, P4, and P6) or by Sanger sequencing (P7)
from a cohort with dystroglycanopathy and severe brain
involvement.40,41 P3, P4, and P7 have at least one trun-
cating mutation in B3GALNT2 and more severe clinical
features than do P1 and P2 with evidence of severe hydro-
cephalus and cobblestone lissencephaly on brain MRI
(Figure 1), leading to a diagnosis of WWS, the most severe
form of dystroglycanopathy. P4 had two affected siblings:
an affected female diagnosed with WWS (P5, for whom
no DNA was available) and another affected sibling who
was diagnosed prenatally with severe hydrocephalus and
ocular malformations based on fetal ultrasound, leading
to a pregnancy termination. The fetal DNA confirmed
the presence of the compound heterozygous B3GALNT2
mutations identified in P4 and carried by the parents. P6
had a less severe presentation, with clinical and radiolog-
ical features of dystroglycanopathy associated with
abnormal white matter signal on T2-weighted MRI images.Figure 1. Individuals with B3GALNT2 Mutations Have Structural Br
(A) Sagittal T1-weighted MRI of P3 demonstrating severe hydroceph
brainstem.
(B) Axial T2-weighted MRI of P2 demonstrating abnormal cerebral w
(C) Coronal T2-weighted MRI of P2 demonstrating cerebellar dyspla
(D) Coronal T2-weighted MRI of P6 demonstrating abnormal cerebr
The AmeAll affected individuals had severe hypotonia and did not
attain any motor milestones. P3, P4, and P5 also had
epilepsy. See Table 2 for further clinical details and
Figure S1 for a summary of the mutations found in P1–
P4, P6, and P7.
Skeletal Muscle Biopsies of Individuals with
B3GALNT2 Mutations Reveal Dystrophic Processes
and Reduced a-DG Glycosylation
A muscle biopsy of the quadriceps performed in P1 at
11 months of age showed features consistent with
muscular dystrophy, including abnormal variation in fiber
size, regenerating fibers, endomysial connective tissue, and
internal nuclei. A muscle biopsy performed in P2 at 2 years
of age showed less severe changes, with no obvious
necrosis. Immunolabeling of laminin a2 with antibodies
to the 80 and 300 kDa fragments showed a slight reduction
of labeling of some fibers in P1 but was normal in P2 (dataain Abnormalities
alus, ponto-cerebellar hypoplasia, and anterior concavity of the
hite matter.
sia and cysts.
al white matter and cerebellar dysplasia.
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Table 2. Summary of Clinical Findings
Affected
Person Sex Origin
Age at
Presentation
Presenting
Symptom
Maximal Motor
Ability
Main Neurologic
Features
Ophthalmologic
Findings
Maximum
CK (U/L)
Brain MRI
Findings Phenotype
P1 M Europe 5 weeks borderline
macrocephaly
few steps
with support
cognitive delay optic nerve hypoplasia 1,132 polymicrogyria,
fronto-temporal
leukoencephalopathy,
cerebellar cysts
MEB/FCMD-like
P2 M Turkey 17 months motor and
cognitive delays
few steps
with support
cognitive
impairment
none 894 polymicrogyria,
fronto-temporal
leukoencephalopathy,
brainstem and pontine
hypoplasia, cerebellar
dysplasia, cerebellar cysts
MEB/FCMD-like
P3 F USA (white) birth hypotonia, severe
hydrocephalus
roll over
(halfway)
epilepsy and
absent cognitive
development
optic nerve hypoplasia,
bilateral lens opacities
21,000 severe hydrocephalus,
cobblestone lissencephaly,
ponto-cerebellar hyoplasia
WWS/WWS-like
P4 M South Africa birth hypotonia, severe
hydrocephalus
no motor
milestones
attained
epilepsy and
absent cognitive
development
right-sided congenital
glaucoma, left-sided
microphthalmia and
cataract, buphthalmia
6,964 severe hydrocephalus,
cobblestone lissencephaly
WWS/WWS-like
P5 F South Africa birth hypotonia,
hydrocephalus
no motor
milestones
attained
epilepsy and
absent cognitive
development
blindness NA hydrocephalus, cobblestone
lissencephaly, profound
hypomyelination
WWS/WWS-like
P6 F Saudi Arabia 15 months motor and
cognitive delays
bottom
shuffling
cognitive
impairment
none (no formal
ophthalmologic exam)
1,740 fronto-temporal
leukoencephalopathy,
cerebellar dysplasia
MEB/FCMD-like
P7 M USA (Hispanic) birth hypotonia and
respiratory distress
no motor
milestones
attained
absent cognitive
development
bilateral
microphthalmia
1,086 severe hydrocephalus,
cobblestone lissencephaly
WWS/WWS-like
Abbreviations are as follows: CK, creatine kinase; M, male; F, female; FCMD, Fukuyama congenital muscular dystrophy; MEB, muscle-eye-brain disease; NA, not available; and WWS, Walker-Warburg syndrome. DNA was not
available for P5.
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Figure 2. Functional a-DG Glycosylation
Is Reduced in Individuals with B3GALNT2
Mutations
An examination of skeletal muscle cryosec-
tions from control, P1, and P2 revealed
that glycosylated a-DG is reduced in indi-
viduals with B3GALNT2 mutations (P1
and P2) whereas b-DG was well preserved.
Staining with the GT20ADG antibody
against the core a-DG protein showed
that the core was better preserved in P2
than in P1 as some variability was seen
among the fibers.not shown). Labeling of a-DG with IIH6 was variably
reduced whereas labeling of b-DG, of core a-DG (Figure 2),
and of laminin chains a5, b1, and g1 was normal (data not
shown).
Immunoblotting for a-DG with the IIH6 antibody in
muscle protein lysates showed a profound reduction in
a-DG functional glycosylation for P1 and a mild reduction
with a lower molecular weight for P2. There was no change
in the amount of b-DG (Figure 3). Immunoblotting for
IIH6 in fibroblasts of both P1 and P2 showed a severe
reduction in the IIH6 epitope (Figure S2).
Affected Fibroblasts with Mutations in B3GALNT2
Have Reduced a-DG Glycosylation
Flow cytometry was used to assess the level of functional
a-DG glycosylation in P1 and P2 fibroblasts compared totion in MFI in both P1 and P2 compared to controls (each fibroblast sample was analyzed
control (line A) was used to remove background from the populations incubated with all th
The American Journal of Humanthe fibroblasts of two nonpathologi-
cal controls (previously found to
have normal a-DG glycosylation byimmunohistochemistry and immunoblot [not shown]).
The level of functional a-DG glycosylation was evaluated
by the fluorescence intensity of the IIH6 epitope conju-
gated to streptavidin-PE.
Flow cytometry showed that P1 and P2 fibroblasts were
reduced in functionally glycosylated a-DG compared to
the two controls (p< 0.05). The controls had 75.28 average
and 79.98 mean fluorescence intensity (MFI), whereas
B3GALNT2 fibroblasts have 33.53 average MFI (P1) and
28.5 average MFI (P2), suggesting a profound reduction
of the IIH6 epitope (Figure 3; Table S3).
To further validate this technique, in addition to
the nonpathological fibroblast controls, we also tested
fibroblasts from an individual with a ryanodine re-
ceptor mutation (RYR1 [MIM 180901]) and from an indi-
vidual with an a-glucosidase mutation (GAA [MIMFigure 3. Immunoblotting of Muscle
Protein Lysate and Flow Cytometry of
P1 and P2 Fibroblasts Reveals Aberrant
a-DG Glycosylation in P1 and P2
(A) The membrane was incubated with
a-DG IIH6 and b-DG antibodies. P1
showed a profound reduction in a-DG
IIH6 accumulation compared to the
control whereas in P2 the level of IIH6
was similar to the control, but a slight
shift in molecular weight was seen in
both individuals. There was no change in
b-DG levels.
(B) Flow cytometry was utilized to assess
the level of functional a-DG glycosylation
in P1 and P2 compared to nonpathological
controls. The level of functional a-DG
glycosylation was evaluated by the fluores-
cence intensity of the IIH6 epitope conju-
gated to streptavidin-PE. This histogram
shows the mean fluorescence intensity
(MFI) of the IIH6 epitope. The MFI of the
controls depicted in the histogram were
75.28 (line D) and 79.98 (line E), whereas
P1 (line C) and P2 (line B) had MFI values
of 33.53 and 28.5, respectively. There is
a statistically significant (p < 0.05) reduc-
three times). The secondary antibody-only
ree antibodies.
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Figure 4. Transfection of C212 Myoblasts with Wild-Type and
Mutant B3GALNT2
C2C12 myoblasts were transfected with B3GALNT2 pcDNA 3.1
V5/HIS-TOPO (either wild-type or with the missense mutation
c.740G>A [p.Gly247Glu], c.875G>C [p.Arg292Pro], c.802G>A
[p.Val268Met]). Wild-type B3GALNT2 colocalized with the ER-
specific marker ERp72. The c.740G>A (p.Gly247Glu) and
c.802G>A (p.Val268M) mutations caused the enzyme to localize
differently than the wild-type enzyme, but the c.875G>C
(p.Arg292Pro) mutation did not alter the subcellular localization
compared to wild-type.232300]). These fibroblasts all had MFI values that
were not statistically different than the controls listed
above (Table S3). Additionally, two individuals carrying
mutations in two genes previously associated with dystro-
glycanopathy (POMT1 and FKRP) had significantly
(p < 0.05) reduced MFI values compared to both the non-
pathological and the pathological controls described here
(Table S3).
B3GALNT2 Localizes to the Endoplasmic Reticulum
and This Localization Is Disrupted by
Dystroglycanopathy Mutations
In order to assess the functional effect of the B3GALNT2
mutations, we examined the localization of the wild-type
and mutant proteins. Wild-type B3GALNT2 colocalized
with the ER-specific marker ERp72 (Figure 4), suggesting
B3GALNT2 localization to the ER despite the absence of
an obvious ER retention signal. Like wild-type, the
c.875G>C (p.Arg292Pro) mutant colocalized with the ER
marker, indicating that this mutation did not alter the
protein localization (Figure 4). However, both c.740G>A
(p.Gly247Glu) and c.802G>A (p.Val268Met) mutants
had diffuse localization compared to wild-type and the360 The American Journal of Human Genetics 92, 354–365, March 7ER marker (Figure 4), suggesting that these mutations
disrupt the ER localization of B3GALNT2.
Knockdown of Zebrafish b3galnt2 Recapitulates
Several Aspects of the Human Phenotypes Including
Reduced a-DG Glycosylation
To analyze the role of B3GALNT2 in vivo, we used
zebrafish as a vertebrate model. Human B3GALNT2
has a single ortholog in zebrafish (Ensembl ID
ENSDARG00000046133). Zebrafish B3galnt2 is 53% iden-
tical to human B3GALNT2 and the amino acid sequence
of the galactosyltransferase domain alone is conserved
with 68.5% identity. Publically available in situ hybridiza-
tion data indicate that b3galnt2 is ubiquitously expressed
at early stages of zebrafish development, becoming
more anteriorly localized as development progresses
(ZFIN database). By using RT-PCR, we confirmed that
b3galnt2 expression was detectable throughout early devel-
opment (Figure S3).
To knock down b3galnt2 in zebrafish embryos, we in-
jected a translation-blocking (TB) morpholino (4 ng)
together with a p53 morpholino (2 ng) to reduce p53-
mediated off-target effects.42,43 Under confocal micros-
copy, we showed that the expression of GFP-tagged
B3galnt2 was effectively suppressed, confirming the mor-
pholino specificity (Figure 5). Zebrafish b3galnt2 knock-
down embryos (morphants) showed curved body, mild
retinal degeneration, and severely impaired motility
(Figure 5). Similar to fktn, fkrp, and ispd morphants,19
b3galnt2 morphants recapitulated the hydrocephalus
phenotype present in P3, P4, and P7. To further confirm
the morpholino specificity, we injected a b3galnt2 splice-
blocking morpholino, which also caused very similar
phenotypes (data not shown).
To characterize the muscle phenotype, we performed
immunofluorescence staining. Compared to the V-shaped
somite boundaries flanking straight muscle fibers in wild-
type embryos, b3galnt2 morphants consistently showed
slightly U-shaped somites and disordered muscle fibers
(Figure 5). Laminin staining revealed occasional gaps in
the myosepta (the connective tissues where the muscle
fibers anchor), suggesting disruption of the extracellular
matrix (Figure 5). Next, we quantified the severity of
muscle damage by Evans blue dye (EBD) assay.44 EBD pene-
trates compromised sarcolemma or accumulates at lesions
in muscle. Compared to wild-type embryos, b3galnt2mor-
phants showed more severely damaged muscle with
increased number of lesions, ranging from less than 10 to
more than 30 lesions per embryo (Figure 5).
Immunoblot analysis with the IIH6 antibody on protein
extracts from wild-type embryos and b3galnt2 morphants
showed a reduction of the IIH6 signal in b3galnt2 mor-
phants, indicating that knockdown of b3galnt2 led to
reduced functional glycosylation of a-DG. This is consis-
tent with the human data and strongly suggests that this
may be the molecular mechanism behind the phenotypes
described., 2013
Figure 5. b3galnt2 Knockdown Zebrafish Embryos Have Muscle Defects and Hypoglycosylated a-DG at 48 hpf
(A) Whole-mount pictures of live embryos show gross morphological defects.
(B) Immunofluorescence staining by an antibody against b-DG and differential interference contrast (DIC) microscopy showed that the
muscle fibers are disordered. One sample fiber is highlighted in red.
(C) Immunofluorescence staining by an antibody against laminin (LAM) shows gaps in themyosepta of knockdown embryos and degen-
eration of the extracellular matrix.
(D) Evans blue dye assay (EBD) highlights frequent lesions between muscle fibers in b3galnt2morphants, which are very rarely seen in
wild-type embryos (the same image is shown with and without DIC microscopy).
(A–D) b3galnt2 MO: b3galnt2 TB morpholino (4 ng) coinjected with p53 TB morpholino (2 ng). Scale bars represent 50 mm.
(E) Immunoblotting by isolatedmicrosome protein from 48 hpf embryos and IIH6 antibody showed a reduction in glycosylated a-DG in
the b3galnt2 knockdown embryos. b3galnt2MO: b3galnt2 TB morpholino (5 ng) coinjected with p53 TB morpholino (2.5 ng). dag1MO:
dag1 TB morpholino (5 ng).Discussion
In this study we describe the use of exome and Sanger
sequencing for the identification of mutations inThe AmeB3GALNT2 in six dystroglycanopathy-affected families
characterized by the invariable presence of structural brain
involvement and, in some severe cases, ocular involve-
ment. The spectrum of severity in individuals withrican Journal of Human Genetics 92, 354–365, March 7, 2013 361
Figure 6. Schematic Diagram of
B3GALNT2 Exons, Mutations, and Align-
ment
(A) B3GALNT2 is 57,249 bp in length
and contains 12 exons that are tran-
scribed into a 4,720 bp RNA transcript
(NM_152490.2). The coding sequence of
B3GALNT2 is 2,015 bp long and contains
500 amino acids. This schematic diagram
indicates the location of the known galac-
tosyltransferase domain (black line indi-
cating position in the protein, amino acids
307–457) as well as the location of the
mutations found in affected individuals.
These mutations are listed in Table 2.
(B) Alignment of a section of the protein
sequence of B3GALNT2 in six species
(Homo sapiens, Pan troglodytes, Mus muscu-
lus, Danio rerio, Canis lupus, Bos taurus)
shows that the missense mutations identi-
fied in affected individuals (c.740G>A
[p.Gly247Glu] and c.875G>C [p.Arg292-
Pro] in P1, c.755T>G [p.Val252Gly] in P4,
c.802G>A [p.Val268Met] in P6) are well
conserved across these species. This
suggests structural or functional impor-
tance for these residues. Proteinalignments
were performed with NCBI Homologene
software.B3GALNT2 mutations ranged from severe WWS to mild
MEB-like or FCMD-like conditions45 (Tables 1 and 2). In
terms of correlation between genotype and phenotype,
biallelic loss-of-function mutations were associated with
the most severe phenotype, as demonstrated in P3 and
P7, affected by severe WWS. P1, with compound heterozy-
gosity for two missense mutations in exons 6 and 8 of
B3GALNT2, had a milder CMD phenotype, associated
with less severe structural brain involvement and better
motor and cognitive achievements. Surprisingly, P2, with
a biallelic duplication in exon 1, also presented with
a milder CMD phenotype with brain involvement.
In order to assess the pathogenicity of the missense
mutations found in P1 (c.740G>A [p.Gly247Glu],
c.875G>C [p.Arg292Pro]) and P6 (c.802G>A [p.Val268-
Met]), which do not affect a known functional domain
(Figure 6), we transfected mutated V5-tagged constructs
into C2C12 cells and observed that two of them
(c.740G>A [p.Gly247Glu] and c.802G>A [p.Val268Met])
altered the ER localization, potentially preventing normal
enzymatic function (Figure 4). The missense mutation
(c.875G>C [p.Arg292Pro]) showed no obvious changes
in localization compared to wild-type (Figure 4), but this
amino acid is highly conserved in vertebrates (Figure 6),
so it is likely to be of functional importance. To determine
whether mutations in B3GALNT2 led to a reduction in the
level of functional a-DG glycosylation, we assessed the
muscle and fibroblasts of P1 and P2 bymuscle immunohis-
tochemistry (Figure 2), flow cytometry, and immunoblot-
ting (Figures 3 and S2). Although each technique revealed
some degree of hypoglycosylation, the fact that flow cy-
tometry and immunoblotting of the fibroblasts indicated362 The American Journal of Human Genetics 92, 354–365, March 7a more severe depletion compared to the immunoblot of
muscle protein lysate may be related to tissue-specific
glycosylation of a-DG.5,6,46
Knockdown of zebrafish b3galnt2 recapitulated aspects
of the human phenotype including dystrophic muscle,
hydrocephalus, and reduced functional a-DG glycosyla-
tion. The myotomal lesions revealed by EBD (Figure 5)
are very similar to the phenotype caused by knockdown
of other known dystroglycanopathy genes including
FKTN and FKRP.43
a-DG is heavily O-mannosylated in its mucin-like
domain.1 These mannose residues can themselves be
modified. For example, a b1,2 linked N-acetyl glucosamine
(GlcNAc) group can be added by POMGNT138 or a b1,4
linkedGlcNAc group can be added by an unknownGlcNAc
transferase.38 We speculate that after the addition of b1,4
linked GlcNAc, B3GALNT2 completes the trisaccharide
GalNAc-b1,3-GlcNAc-b1,4-Man.38,39 This trisaccharide is
believed to contain a LARGE-dependent 6-O-phosphoryl
modification on the mannose residue38 and is required
for ligand binding glycan of a-DG.37 There may be other
protein targets of B3GALNT2, which are currently
unknown.37 We propose that the phosphorylated trisac-
charide is produced in the endoplasmic reticulum, as
suggested by the subcellular localization of B3GALNT2.
AlthoughO-mannosylation occurs in the ER andO-GalNA-
cylation in the Golgi, it has been recently suggested that
certain GalNAc glycosyltransferases can be located in the
ER,47 which appears to be the case for B3GALNT2.
Although further study is needed to establish the precise
role of B3GALNT2 in the glycosylation of a-DG, our
data show that mutations in B3GALNT2 can cause, 2013
dystroglycanopathy. Furthermore, this study provides
insight into the complexity of a-DG glycoslyation and
illustrates the utility of whole-exome sequencing with
functional analysis for the identification of mutations
that cause dystroglycanopathies. Additional genetic
discoveries will help to complete the understanding of
a-DG glycosylation as well as elucidate the pathological
mechanisms underlying the muscle and brain phenotypes
associated with these diseases.Supplemental Data
Supplemental Data include five figures and three tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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